Dara Pincas

About Dara Pincas

Dara Pincas is a senior biopharma legal executive and current director of 89bio, Inc. (ETNB) following its acquisition by Roche; she was appointed to ETNB’s board at the merger close in October 2025 . She serves as Head of Global Legal Pharma, Senior Vice President, General Counsel, Chief Compliance Officer, and Corporate Secretary of Genentech (Roche Group), after leading Roche Pharmaceuticals Legal as Head of Legal (July 2023–September 2025) . Pincas holds a J.D. from the University of Michigan Law School (Class of 1997) and is an experienced in‑house and government lawyer with prior roles at Pfizer, Genentech and the U.S. Federal Trade Commission .

Past Roles

Organization	Role	Years	Strategic Impact
Genentech, Inc. (Roche Group)	Head of Global Legal Pharma; SVP, General Counsel, Chief Compliance Officer, Corporate Secretary	2025–present	Oversees global legal and compliance for Genentech; corporate secretary function .
Roche Pharmaceuticals	Head of Legal	2023-07 to 2025-09	Led legal for $45B revenue pharma business within Roche [https://jewishfed.org/bio/dara-pincas/#::text=Dara%20attended%20an%20International%20School].
89bio, Inc. (ETNB)	Director	2025-10-30 to present	Installed as director at Effective Time of Roche tender/merger; prior board resigned .
Genentech, Inc.	Senior associate general counsel; led 40‑lawyer Healthcare Law Group (prior role)	n/d	Led U.S. healthcare law counseling team .
Pfizer, Inc.	General Counsel, Pfizer Israel (prior role)	n/d	Country GC; cross‑border pharma operations support .
U.S. Federal Trade Commission	Attorney (prior role)	n/d	Competition/consumer protection enforcement; mentorship under Commissioner Tom Leary .

External Roles

Organization	Role	Years	Notes
Jewish Community Federation and Endowment Fund (Bay Area)	Israel Subcommittee Chair; Board leader	n/d	Community leadership; Israel and social impact committees .
JCC of the East Bay; Contra Costa Jewish Day School	Board involvement	n/d	Non‑profit governance .

Fixed Compensation

Not disclosed by ETNB for Pincas. She was not a named executive officer or director in ETNB’s 2024 proxy period, and post‑merger director compensation for the reconstituted board was not disclosed in ETNB filings .

Performance Compensation

Not disclosed by ETNB for Pincas. No ETNB filings detail any RSU/PSU/option or bonus arrangements for her role as post‑merger director .

Equity Ownership & Alignment

Beneficial ownership: No ETNB security ownership reported for Pincas. The most recent Security Ownership table (as of March 31, 2025) does not include her; it predates her appointment and reflects the pre‑merger public company shareholder base .
Pledging/hedging: ETNB policy prohibits hedging/pledging by directors and officers; no pledging by Pincas is disclosed .

Employment Terms

Indemnification and D&O insurance: The merger agreement requires maintaining D&O indemnification/exculpation and a six‑year prepaid D&O “tail” policy for pre‑merger directors and officers; the Surviving Corporation’s charter/bylaws must preserve indemnification provisions post‑close . (Note: tail specifically protects pre‑merger fiduciaries; post‑closing indemnification is maintained in organizational documents for directors.)
As a director of a wholly owned subsidiary post‑merger, her employment/compensation terms are governed by the parent; no ETNB‑specific severance or change‑of‑control economics for Pincas are disclosed .

Board Governance

Board service at ETNB: Appointed as director at the merger Effective Time (Oct 2025) when Roche’s Merger Sub directors (including Pincas) became the board; all prior directors resigned .
Committees and attendance: Not disclosed post‑merger. Pre‑merger committee structure applied to the prior board only .
Independence: Pincas is a senior executive of the acquiring parent (Genentech/Roche); therefore, she would not be considered independent under Nasdaq standards. ETNB is now a wholly owned subsidiary of Roche; public‑company independence requirements no longer apply .

Investment Implications

Alignment and incentives: Pincas’ role is as a parent‑company legal executive and post‑merger director of ETNB; there are no ETNB equity grants or director compensation disclosures to analyze for pay‑for‑performance. With ETNB now a wholly owned Roche subsidiary, minority shareholder alignment and say‑on‑pay considerations are moot .
Governance and control: Her dual role (Genentech/Roche executive and ETNB director) signals direct parent oversight and limited board independence—typical for a private, wholly owned subsidiary. Strategic, capital allocation, and disclosure decisions reside with Roche/Genentech .
Trading signals: No insider selling/vesting pressure or ETNB equity ownership by Pincas is disclosed. Post‑close, ETNB equity is no longer publicly traded; trading catalysts reside with Roche (and any CVR milestones for former ETNB public holders) rather than with ETNB governance moves .

Key references: Appointment to ETNB board (Item 5.02) ; ETNB now wholly owned by Roche post‑tender/merger ; Dara Pincas senior roles at Roche/Genentech and prior Head of Legal (2023–2025) ; legal career background and education ; community board roles .